الدراسة أثبتت أن لقاح فايزر ضد كورونا متحور أميكرون يتلاشى بعد عدة أسابيع قليلة!!!!

 

Pfizer’s COVID Vaccine Protection Against Omicron Fades After a Few Weeks: Study

By Jack Phillips

 

May 16, 2022 Updated: May 16, 2022

biggersmaller 

الدراسة أثبتت أن لقاح فايزر ضد كورونا متحور أميكرون يتلاشى بعد عدة أسابيع قليلة

The protection afforded against the Omicron coronavirus variant fades quickly after a second and third dose of Pfizer–BioNtech’s COVID-19 vaccine, according to a peer-reviewed study published in the JAMA Network.

الحماية الممنوحة ضد متغير فيروس كورونا أوميكرون تتلاشى بسرعة بعد الجرعة الثانية والثالثة من لقاح  COVID-19 من شركة  فايزر Pfizer – BioNtech ، وفقًا لدراسة تمت مراجعتها من قِبل النشرات العلمية ونشرت في شبكة JAMA.

A Danish study published in the JAMA Network on May 13 found that there was a rapid decline in Omicron-specific serum neutralizing antibodies only a few weeks after the administration of the second and third doses of the vaccine.

وجدت دراسة دنماركية نُشرت في شبكة JAMA في 13 مايو أن هناك انخفاضًا سريعًا في الأجسام المضادة المعادلة لمصل أوميكرون بعد أسابيع قليلة فقط من إعطاء الجرعتين الثانية والثالثة من اللقاح.

 

The study evaluated 128 adults who were vaccinated, and of that number, 73 people received two doses of the Pfizer vaccine, and 55 people received three doses between January 2021 and October 2021 or were previously infected before February 2021, and then vaccinated.

قامت الدراسة بتقييم 128 بالغًا تم تطعيمهم ، ومن هذا العدد تلقى 73 شخصًا جرعتين من لقاح فايزر ، وتلقى 55 شخصًا ثلاث جرعات بين يناير 2021 وأكتوبر 2021 أو أصيبوا سابقًا قبل فبراير 2021 ، ثم تم تطعيمهم.

“Our study found a rapid decline in Omicron-specific serum neutralizing antibody titers only a few weeks after the second and third doses,” an abstract of the study reads. “The observed decrease in population neutralizing antibody titers corresponds to the decrease in vaccine efficacy against polymerase chain reaction–confirmed Omicron infection in Denmark and symptomatic Omicron infection in the United Kingdom.”

ملخص الدراسة: "وجدت دراستنا انخفاضًا سريعًا في عيار الأجسام المضادة الخاصة بأوميكرون المصل المحدد بعد أسابيع قليلة فقط من الجرعتين الثانية والثالثة". "الانخفاض الملحوظ في عيار الأجسام المضادة المعادلة للسكان يتوافق مع انخفاض فعالية اللقاح ضد تفاعل البلمرة المتسلسل - عدوى Omicron المؤكدة في الدنمارك وعدوى Omicron المصحوبة بأعراض في المملكة المتحدة."

The antibody levels, which are associated with protection against future infections, dropped within a few weeks of getting the vaccine doses. They were also much lower than the antibodies specific to the Delta and original COVID-19 strains, according to the study.

انخفضت مستويات الأجسام المضادة ، المرتبطة بالحماية من العدوى المستقبلية ، في غضون أسابيع قليلة من الحصول على جرعات اللقاح. كانت أيضًا أقل بكثير من الأجسام المضادة الخاصة بدلتا وسلالات COVID-19 الأصلية ، وفقًا للدراسة.

The proportion of Omicron-specific antibodies fell to 53 percent between the eighth and tenth week from 76 percent four weeks after the second dose. At weeks 12 to 14, these levels dropped even more to only 19 percent, according to the study.

انخفضت نسبة الأجسام المضادة الخاصة بأوميكرون إلى 53 بالمائة بين الأسبوعين الثامن والعاشر من 76 بالمائة بعد أربعة أسابيع من الجرعة الثانية. في الأسابيع من 12 إلى 14 ، انخفضت هذه المستويات أكثر إلى 19 في المائة فقط ، وفقًا للدراسة.

 

Those antibodies increased with a third dose, increasing 21-fold three weeks after the dose before dropping to eightfold at week four. But with the third dose, antibody levels dropped as early as three weeks, falling 5.4-fold between the third and eighth week, the researchers said.

زادت هذه الأجسام المضادة بجرعة ثالثة ، وزادت بمقدار 21 ضعفًا بعد ثلاثة أسابيع من الجرعة قبل أن تنخفض إلى ثمانية أضعاف في الأسبوع الرابع. لكن مع الجرعة الثالثة ، انخفضت مستويات الأجسام المضادة في وقت مبكر يصل إلى ثلاثة أسابيع ، وانخفضت بمقدار 5.4 أضعاف بين الأسبوعين الثالث والثامن ، كما قال الباحثون.

They concluded that it may be needed to provide additional booster doses to combat the Omicron variant, which emerged last fall, primarily among older individuals.

وخلصوا إلى أنه قد تكون هناك حاجة لتوفير جرعات معززة إضافية لمكافحة متغير أوميكرون  الذي ظهر في الخريف الماضي ، بشكل أساسي بين الأفراد الأكبر سنًا.

However, a study from Israeli researchers published in early April in the New England Journal of Medicine found that a fourth dose, or a second booster, of the Pfizer vaccine, doesn’t offer strong protection.

“Overall, these analyses provided evidence for the effectiveness of a fourth vaccine dose against severe illness caused by the omicron variant, as compared with a third dose administered more than 4 months earlier,” the study’s authors wrote at the time, after analyzing data from the Israeli Ministry of Health. “For confirmed infection, a fourth dose appeared to provide only short-term protection and a modest absolute benefit.”

هيئة الغذاء والدواء الأمريكية تقيد إستخدام لقاح جونسون لأنه يسبب تجلطات دموية

Johnson & Johnson Covid-19 Vaccine Use Limited By US Food And Drug Administration Advisory

The FDA said in a statement that the change is because of a risk of a clotting condition called thrombosis with thrombocytopenia syndrome (TTS) from use of the vaccine.
Thursday’s announcement is sure to fuel further concerns among those who have resisted Covid-19 vaccinations. Many people have cited concerns about vaccinations that were rushed to market without the usual years-long vetting on potential long-term effects. While those fears have been derided as “conspiracy theories,” today’s ruling will give pause on whether the resistance was grounded in logic.


“We’ve been closely monitoring the Janssen COVID-19 Vaccine and occurrence of TTS following its administration and have used updated information from our safety surveillance systems to revise the EUA,” said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research. “We recognize that the Janssen COVID-19 Vaccine still has a role in the current pandemic response in the United States and across the global community. … Today’s action demonstrates the robustness of our safety surveillance systems and our commitment to ensuring that science and data guide our actions.”


The new marching orders applies to first shots and any boosters.


Despite the warning, the FDA said the J&J vaccine’s blood clotting problem is still better than not being vaccinated. It gave several examples of those who may still benefit, including: :


Those who had a severe allergic reaction to an mRNA vaccine, such as those from Pfizer/BioNTech or Moderna;


Those with personal concerns about the mRNA vaccines who would remain unvaccinated without the J&J vaccine;


Those with limited access to mRNA Covid-19 vaccines.


Moe than 18.7 million doses of the J&J vaccine have been administered in the US, according to the US Centers for Disease Control and Prevention. It estimated that 7.7% of those who received the J&J vaccine are considered fully vaccinated.


In an updated fact sheet on the vaccine, the FDA says that 15% of TTS cases have been fatal.


The agency’s updated analysis of the vaccine includes cases reported to its Vaccine Adverse Events Reporting System (VAERS) database through March 18. The FDA says it has confirmed 60 cases of TTS, including nine deaths.